The long and winding road that leads to a cure for epidermolysis bullosa

Regenerative Medicine

Volumn 8, Issue 4, 2013, Pages 467-481

  Carulli, Sonia ^a   Contin, Roberta ^a   De Rosa, Laura ^a   Pellegrini, Graziella ^a   De Luca, Michele ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

cell therapy; clinical trial; epidermis; epidermolysis bullosa; gene therapy; GMP; holoclones; regenerative medicine; stem cells; tissue engineering

Indexed keywords

GENE THERAPY AGENT; PROTEIN COL7A1; PROTEIN LAMB3; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CELL REGENERATION; DERMOEPIDERMAL JUNCTION; DRUG EFFICACY; EPIDERMOLYSIS BULLOSA; EX VIVO GENE TRANSFER; GENE REPLACEMENT THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KERATINOCYTE; LYMPHOPROLIFERATIVE DISEASE; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SKIN FIBROBLAST; SQUAMOUS EPITHELIUM; STEM CELL GENE THERAPY; VIRAL GENE THERAPY; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

CELL- AND TISSUE-BASED THERAPY; EPIDERMOLYSIS BULLOSA; HUMANS; REGENERATIVE MEDICINE;

EID: 84880236346     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.13.33     Document Type: Review

References (132)

1. Fine JD, Eady RA, Bauer EA et al. The classification of inherited epidermolysis bullosa (EB): Report of the third international consensus meeting on diagnosis and classification of EB. J. Am. Acad. Dermatol. 58(6), 931-950 (2008
2. Groves RW, Liu L, Dopping-Hepenstal PJ et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J. Invest. Dermatol. 130(6), 1551-1557 (2010
3. Pigors M, Kiritsi D, Krümpelmann S et al. Lack of plakoglobin leads to lethal congenital epidermolysis bullosa: A novel clinico-genetic entity. Hum. Mol. Genet. 20(9), 1811-1819 (2011
4. Liu L, Dopping-Hepenstal PJ, Lovell PA et al. Autosomal recessive epidermolysis bullosa simplex due to loss of BPAG1-e expression. J. Invest. Dermatol. 132(3 Pt 1), 742-744 (2012
5. McGrath JA, Stone KL, Begum R et al. Germline mutation in EXPH5 implicates the Rab27B effector protein Slac2-b in inherited skin fragility. Am. J. Hum. Genet. 91(6), 1115-1121 (2012
6. Fine JD, Johnson LB, Weiner M et al. Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: Experience of the National Epidermolysis Bullosa Registry, 1986-2002. J. Hand Surg. Br. 30(1), 14-22 (2005
7. Fine JD, Johnson LB, Weiner M et al. Inherited epidermolysis bullosa and the risk of death from renal disease: Experience of the National Epidermolysis Bullosa Registry. Am. J. Kidney Dis. 44(4), 651-660 (2004
8. Yuen WY, Jonkman MF. Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: Report of 7 cases and a review of the literature. J. Am. Acad. Dermatol. 65(4), 780-789 (2011
9. Barrandon Y, Green H. Three clonal types of keratinocyte with different capacities for multiplication. Proc. Natl Acad. Sci. USA 84(8), 2302-2306 (1987
10. Pellegrini G, Golisano O, Paterna P et al. Location and clonal analysis of stem cells and their differentiated progeny in the human ocular surface. J. Cell Biol. 145(4), 769-782 (1999
11. Rochat A, Claudinot S, Nicolas M, Barrandon Y. Stem cells and skin engineering. Swiss Med. Wkly 137(Suppl. 155), S49-S54 (2007
12. Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G. Limbal stem-cell therapy and long-Term corneal regeneration. N. Engl. J. Med. 363(2), 147-155 (2010
13. Gallico GG 3rd, O'Connor NE, Compton CC, Kehinde O, Green H. Permanent coverage of large burn wounds with autologous cultured human epithelium. N. Engl. J. Med. 311(7), 448-451 (1984
14. Pellegrini G, Traverso CE, Franzi AT, Zingirian M, Cancedda R, De Luca M. Long-Term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet 349(9057), 990-993 (1997
15. Ronfard V, Rives JM, Neveux Y, Carsin H, Barrandon Y. Long-Term regeneration of human epidermis on third degree burns transplanted with autologous cultured epithelium grown on a fibrin matrix. Transplantation 70(11), 1588-1598 (2000
16. Stanley JR, Rubinstein N, Klaus-Kovtun V. Epidermolysis bullosa acquisita antigen is synthesized by both human keratinocytes and human dermal fibroblasts. J. Invest. Dermatol. 85(6), 542-545 (1985
17. Chen YQ, Mauviel A, Ryynanen J, Sollberg S, Uitto J. Type VII collagen gene expression by human skin fibroblasts and keratinocytes in culture: Influence of donor age and cytokine responses. J. Invest. Dermatol. 102(2), 205-209 (1994
18. König A, Bruckner-Tuderman L. Epithelial-mesenchymal interactions enhance expression of collagen VII in vitro. J. Invest. Dermatol. 96(6), 803-808 (1991
19. De Luca M, Pellegrini G, Green H. Regeneration of squamous epithelia from stem cells of cultured grafts. Regen. Med. 1(1), 45-57 (2006
20. Mavilio F, Pellegrini G, Ferrari S et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 12(12), 1397-1402 (2006
21. Mathor MB, Ferrari G, Dellambra E et al. Clonal analysis of stably transduced human epidermal stem cells in culture. Proc. Natl. Acad. Sci. USA 93(19), 10371-10376 (1996
22. Dellambra E, Vailly J, Pellegrini G et al. Corrective transduction of human epidermal stem cells in laminin-5-Dependent junctional epidermolysis bullosa. Hum. Gene Ther. 9(9), 1359-1370 (1998
23. Siprashvili Z, Nguyen NT, Bezchinsky MY, Marinkovich MP, Lane AT, Khavari PA. Long-Term type VII collagen restoration to human epidermolysis bullosa skin tissue. Hum. Gene Ther. 21(10), 1299-1310 (2010
24. Baldeschi C, Gache Y, Rattenholl A et al. Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum. Mol. Genet. 12(15), 1897-1905 (2003
25. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644), 415-419 (2003
26. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118(9), 3132-3142 (2008
27. Boztug K, Schmidt M, Schwarzer A et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363(20), 1918-1927 (2010
28. Aiuti A, Bacchetta R, Seger R, Villa A, Cavazzana-Calvo M. Gene therapy for primary immunodeficiencies: Part 2. Curr. Opin. Immunol. 24(5), 585-591 (2012
29. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348(3), 255-256 (2003
30. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350(9), 913-922 (2004
31. Howe SJ, Mansour MR, Schwarzwaelder K et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118(9), 3143-3150 (2008
32. Stein S, Ott MG, Schultze-Strasser S et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16(2), 198-204 (2010
33. Aiuti A, Cattaneo F, Galimberti S et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360(5), 447-458 (2009
34. Bushman F, Lewinski M, Ciuffi A et al. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 3(11), 848-858 (2005
35. Cavazza A, Moiani A, Mavilio F. Mechanisms of retroviral integration and mutagenesis. Hum. Gene Ther. 24(2), 119-131 (2013
36. Yu SF, von Rüden T, Kantoff PW et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 83(10), 3194-3198 (1986
37. Zufferey R, Dull T, Mandel RJ et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72(12), 9873-9880 (1998
38. Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J. Virol. 72(10), 8150-8157 (1998
39. Zychlinski D, Schambach A, Modlich U et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16(4), 718-725 (2008
40. Montini E, Cesana D, Schmidt M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119(4), 964-975 (2009
41. Modlich U, Navarro S, Zychlinski D et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and g retroviral vectors. Mol. Ther. 17(11), 1919-1928 (2009
42. Di Nunzio F, Maruggi G, Ferrari S et al. Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors. Mol. Ther. 16(12), 1977-1985 (2008
43. Titeux M, Pendaries V, Zanta-Boussif MA et al. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa. Mol. Ther. 18(8), 1509-1518 (2010
44. Chen M, O'Toole EA, Muellenhoff M, Medina E, Kasahara N, Woodley DT. Development and characterization of a recombinant truncated type VII collagen minigene'. Implication for gene therapy of dystrophic epidermolysis bullosa. J. Biol. Chem. 275(32), 24429-24435 (2000
45. Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther. 10(13), 1099-1104 (2003
46. Ortiz-Urda S, Thyagarajan B, Keene DR et al. Stable nonviral genetic correction of inherited human skin disease. Nat. Med. 8(10), 1166-1170 (2002
47. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA. PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum. Gene Ther. 14(9), 923-928 (2003
48. Chalberg TW, Portlock JL, Olivares EC et al. Integration specificity of phage phiC31 integrase in the human genome. J. Mol. Biol. 357(1), 28-48 (2006
49. Maruggi G, Porcellini S, Facchini G et al. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol. Ther. 17(5), 851-856 (2009
50. Throm RE, Ouma AA, Zhou S et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113(21), 5104-5110 (2009
51. Loew R, Meyer Y, Kuehlcke K et al. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating g-retroviral vectors using targeted integration. Gene Ther. 17(2), 272-280 (2010
52. Schucht R, Coroadinha AS, Zanta-Boussif MA et al. A new generation of retroviral producer cells: Predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol. Ther. 14(2), 285-292 (2006
53. Schambach A, Mueller D, Galla M et al. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther. 13(21), 1524-1533 (2006
54. Williams DA, Thrasher AJ, Baum C. Transatlantic consortium spotlights need for changes in gene therapy trials. Mol. Ther. 18(11), 1892 (2010
55. Suerth JD, Maetzig T, Galla M, Baum C, Schambach A. Self-inactivating alpharetroviral vectors with a split-packaging design. J. Virol. 84(13), 6626-6635 (2010
56. Suerth JD, Maetzig T, Brugman MH et al. Alpharetroviral self-inactivating vectors: Long-Term transgene expression in murine hematopoietic cells and low genotoxicity. Mol. Ther. 20(5), 1022-1032 (2012
57. Epstein EH Jr. Molecular genetics of epidermolysis bullosa. Science 256(5058), 799-804 (1992
58. Petek LM, Fleckman P, Miller DG. Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex. Mol. Ther. 18(9), 1624-1632 (2010
59. Höher T, Wallace L, Khan K, Cathomen T, Reichelt J. Highly efficient zinc-finger nuclease-mediated disruption of an eGFP transgene in keratinocyte stem cells without impairment of stem cell properties. Stem Cell Rev. 8(2), 426-434 (2012
60. Murphy WJ, Watkins KP, Agabian N. Identification of a novel Y branch structure as an intermediate in trypanosome mRNA processing: Evidence for trans splicing. Cell 47(4), 517-525 (1986
61. Puttaraju M, Jamison SF, Mansfield SG, Garcia-Blanco MA, Mitchell LG. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat. Biotechnol. 17(3), 246-252 (1999
62. Flouriot G, Brand H, Seraphin B, Gannon F. Natural trans-spliced mRNAs are generated from the human estrogen receptor-A (hER alpha) gene. J. Biol. Chem. 277(29), 26244-26251 (2002
63. Wally V, Klausegger A, Koller U et al. 5′ trans-splicing repair of the PLEC1 gene. J. Invest. Dermatol. 128(3), 568-574 (2008
64. Wally V, Brunner M, Lettner T et al. K14 mRNA reprogramming for dominant epidermolysis bullosa simplex. Hum. Mol. Genet. 19(23), 4715-4725 (2010
65. Dallinger G, Puttaraju M, Mitchell LG et al. Development of spliceosome-mediated RNA trans-splicing (SMaRT) for the correction of inherited skin diseases. Exp. Dermatol. 12(1), 37-46 (2003
66. Koller U, Wally V, Mitchell LG et al. A novel screening system improves genetic correction by internal exon replacement. Nucleic Acids Res. 39(16), e108 (2011
67. Murauer EM, Gache Y, Gratz IK et al. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa. J. Invest. Dermatol. 131(1), 74-83 (2011
68. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2(12), 711-719 (2006
69. Atkinson SD, McGilligan VE, Liao H et al. Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J. Invest. Dermatol. 131(10), 2079-2086 (2011
70. Pendaries V, Gasc G, Titeux M, Tonasso L, Mejía JE, Hovnanian A. siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa. J. Invest. Dermatol. 132(6), 1741-1743 (2012
71. Hickerson RP, Smith FJ, Reeves RE et al. Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J. Invest. Dermatol. 128(3), 594-605 (2008
72. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: The formation of keratinizing colonies from single cells. Cell 6(3), 331-343 (1975
73. Eisenberg M, Llewellyn DM, Moran K, Kerr A. Successful engraftment of cultured human epidermal allograft in a child with recessive dystrophic epidermolysis bullosa. Med. J. Aust. 147(10), 520-521 (1987
74. McGrath JA, Schofield OM, Ishida-Yamamoto A et al. Cultured keratinocyte allografts and wound healing in severe recessive dystrophic epidermolysis bullosa. J. Am. Acad. Dermatol. 29(3), 407-419 (1993
75. Carter DM, Lin AN, Varghese MC, Caldwell D, Pratt LA, Eisinger M. Treatment of junctional epidermolysis bullosa with epidermal autografts. J. Am. Acad. Dermatol. 17(2 Pt 1), 246-250 (1987
76. Eisenberg M, Llewelyn D. Surgical management of hands in children with recessive dystrophic epidermolysis bullosa: Use of allogeneic composite cultured skin grafts. Br. J. Plast. Surg. 51(8), 608-613 (1998
77. Falabella AF, Schachner LA, Valencia IC, Eaglstein WH. The use of tissue-engineered skin (Apligraf) to treat a newborn with epidermolysis bullosa. Arch. Dermatol. 135(10), 1219-1222 (1999
78. Falabella AF, Valencia IC, Eaglstein WH, Schachner LA. Tissue-engineered skin (Apligraf ) in the healing of patients with epidermolysis bullosa wounds. Arch. Dermatol. 136(10), 1225-1230 (2000
79. Fivenson DP, Scherschun L, Choucair M, Kukuruga D, Young J, Shwayder T. Graftskin therapy in epidermolysis bullosa. J. Am. Acad. Dermatol. 48(6), 886-892 (2003
80. Shin KC, Park BY, Kim HK, Kim WS, Bae TH. The use of cultured allogenic keratinocyte grafting in a patient with epidermolysis bullosa simplex. Ann. Dermatol. 23(Suppl. 3), S393-S397 (2011
81. Jonkman MF, de Jong MC, Heeres K et al. 180 kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosa. J. Clin. Invest. 95(3), 1345-1352 (1995
82. Jonkman MF, Scheffer H, Stulp R et al. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell 88(4), 543-551 (1997
83. Pasmooij AM, Pas HH, Bolling MC, Jonkman MF. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. J. Clin. Invest. 117(5), 1240-1248 (2007
84. Jonkman MF, Pasmooij AM. Revertant mosaicism-patchwork in the skin. N. Engl. J. Med. 360(16), 1680-1682 (2009
85. Pasmooij AM, Nijenhuis M, Brander R, Jonkman MF. Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations. J. Invest. Dermatol. 132(5), 1374-1383 (2012
86. Almaani N, Nagy N, Liu L et al. Revertant mosaicism in recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 130(7), 1937-1940 (2010
87. Pasmooij AM, Garcia M, Escamez MJ et al. Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 130(10), 2407-2411 (2010
88. Van Den Akker PC, Nijenhuis M, Meijer G, Hofstra RM, Jonkman MF, Pasmooij AM. Natural gene therapy in dystrophic epidermolysis bullosa. Arch. Dermatol. 148(2), 213-216 (2012
89. Al Aboud K, Al Hawsawi K, Ramesh V. Kindler syndrome: Two additional features. Dermatol. Online J. 9(3), 20 (2003
90. Kiritsi D, He Y, Pasmooij AM et al. Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination. J. Clin. Invest. 122(5), 1742-1746 (2012
91. Lai-Cheong JE, Moss C, Parsons M, Almaani N, Mcgrath JA. Revertant mosaicism in Kindler syndrome. J. Invest. Dermatol. 132(3 Pt 1), 730-732 (2012
92. Schuilenga-Hut PH, Scheffer H, Pas HH, Nijenhuis M, Buys CH, Jonkman MF. Partial revertant mosaicism of keratin 14 in a patient with recessive epidermolysis bullosa simplex. J. Invest. Dermatol. 118(4), 626-630 (2002
93. Smith FJ, Morley SM, McLean WH. Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex. J. Invest. Dermatol. 122(1), 73-77 (2004
94. Pasmooij AM, Pas HH, Deviaene FC, Nijenhuis M, Jonkman MF. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am. J. Hum. Genet. 77(5), 727-740 (2005
95. Wada T, Candotti F. Somatic mosaicism in primary immune deficiencies. Curr. Opin. Allergy Clin. Immunol. 8(6), 510-514 (2008
96. Gostynski A, Deviaene FC, Pasmooij AM, Pas HH, Jonkman MF. Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy. Br. J. Dermatol. 161(2), 444-447 (2009
97. Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J. Clin. Invest. 111(2), 251-255 (2003
98. Woodley DT, Krueger GG, Jorgensen CM et al. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J. Invest. Dermatol. 121(5), 1021-1028 (2003
99. Woodley DT, Remington J, Huang Y et al. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol. Ther. 15(3), 628-635 (2007
100. Fritsch A, Loeckermann S, Kern JS et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J. Clin. Invest. 118(5), 1669-1679 (2008
101. Kern JS, Loeckermann S, Fritsch A et al. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: High stability of collagen VII favors long-Term skin integrity. Mol. Ther. 17(9), 1605-1615 (2009
102. Wong T, Gammon L, Liu L et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 128(9), 2179-2189 (2008
103. Nagy N, Almaani N, Tanaka A et al. HB EGF induces COL7A1 expression in keratinocytes and fibroblasts: Possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 131(8), 1771-1774 (2011
104. Conget P, Rodriguez F, Kramer S et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 12(3), 429-431 (2010
105. Owen M, Friedenstein AJ. Stromal stem cells: Marrow-Derived osteogenic precursors. Ciba Found. Symp. 136, 42-60 (1988
106. Sacchetti B, Funari A, Michienzi S et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131(2), 324-336 (2007
107. Mendez-Ferrer S, Michurina TV, Ferraro F et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308), 829-834 (2010
108. Bianco P, Cao X, Frenette PS et al. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat. Med. 19(1), 35-42 (2013
109. Caplan AI. Mesenchymal stem cells. J. Orthop. Res. 9(5), 641-650 (1991
110. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999
111. Bianco P, Robey PG. Skeletal stem cells. In: Handbook of Adult and Fetal Stem Cells. Lanza RP (Ed.). Academic Press, CA, USA, 415-424 (2004
112. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: Revisiting history, concepts, and assays. Cell Stem Cell 2(4), 313-319 (2008
113. Rinkevich Y, Lindau P, Ueno H, Longaker MT, Weissman IL. Germ-layer and lineage-restricted stem/progenitors regenerate the mouse digit tip. Nature 476(7361), 409-413 (2011
114. Wagers AJ, Weissman IL. Plasticity of adult stem cells. Cell 116(5), 639-648 (2004
115. Seita J, Weissman IL. Hematopoietic stem cell: Self-renewal versus differentiation. Wiley Interdiscip. Rev. Syst. Biol. Med. 2(6), 640-653 (2010
116. Caplan AI. The mesengenic process. Clin. Plast. Surg. 21(3), 429-435 (1994
117. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res. 61(4), 364-370 (2000
118. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418(6893), 41-49 (2002
119. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all postnatal organs and tissues. J. Cell Sci. 119(Pt 11), 2204-2213 (2006
120. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4), 315-317 (2006
121. Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3), 301-313 (2008
122. Caplan AI, Correa D. The MSC: An injury drugstore. Cell Stem Cell 9(1), 11-15 (2011
123. Tolar J, Ishida-Yamamoto A, Riddle M et al. Amelioration of epidermolysis bullosa by transfer of wild-Type bone marrow cells. Blood 113(5), 1167-1174 (2009
124. Fujita Y, Abe R, Inokuma D et al. Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice. Proc. Natl Acad. Sci. USA 107(32), 14345-14350 (2010
125. Wagner JE, Ishida-Yamamoto A, McGrath JA et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N. Engl. J. Med. 363(7), 629-639 (2010
126. Haniffa MA, Collin MP, Buckley CD, Dazzi F Mesenchymal stem cells: The fibroblasts' new clothes? Haematologica 94(2), 258-263 (2009
127. Tolar J Can bone marrow cells cure cutaneous diseases? Presented at: Montagna Symposium on the Biology of Skin, Stevenson, WA, USA, 13-17 October 2011
128. Woodley DT, Keene DR, Atha T et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat. Med. 10(7), 693-695 (2004
129. Remington J, Wang X, Hou Y et al. Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol. Ther. 17(1), 26-33 (2009
130. Woodley DT, Wang X, Amir M et al. Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J. Invest. Dermatol. 133(7), 1910-1913 (2013
131. Simmons PJ, Przepiorka D, Thomas ED, Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 328(6129), 429-432 (1987
132. Bianco P, Gehron Robey P. Marrow stromal stem cells. J. Clin. Invest. 105(12), 1663-1668 (2000 Program Epithelial and Muscle Diseases